TheStreet's Jim Cramer remains bullish on several biotech stocks.
Mylan (MYL) shares are climbing after the company announced a $33 billion bid for rival Perrigo (PRGO), the second offer for the company it made this week.
Biogen (BIIB) shares are declining following the release of the company's first quarter earnings results today.
None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.
Apple provides a fantastic platform, but there are other places to profit in the connected device arena such as NXP Semiconductors.
For Friday, April 24 we watch for quarterly financial results from drug maker Biogen (BIIB), copy machine company Xerox (XRX), and American Airlines (AAL).
Alexion Pharmaceuticals (ALXN) shares dropped after the company reported mixed first quarter financial results and provided weak full year guidance today.
Eli Lilly (LLY) shares are climbing after the company beat analysts first quarter earnings and revenue expectations.
Santhera is scheduled to meet with the FDA in the next few weeks, after which it expects to submit idebenone for approval by the middle of the year.
It's common for drug companies to raise the price of their existing products once or twice per year, every year. The price increases far outpace the rate of inflation.
Teva has a path to complete the deal.
Benchmark indexes closed mixed Tuesday with the S&P 500 and Dow Jones Industrial Average pressured by a series of poor earnings, while the Nasdaq popped on deals news.
Amgen (AMGN) shares are climbing after-hours after the company beat analysts' guidance and raised its own forecast for the coming year.
Mylan will generate a higher stock price for its shareholders in the coming months, deal or no deal.
As Israel's Teva Pharmaceutical Industries (TEVA) unveiled its $82 per share bid for Mylan (MYL) Tuesday, the hostile takeover attempt may be a harbinger of things to come.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV